Home › Posts tagged Pembrolizumab [Keytruda]
Blog Archives

Variables of prospective response rates of PD-1/PD-L1 based therapies across cancers

Posted on by by Posted in Genetic Background, Genetic Predisposition, New Research, On The Horizon, Personalized Medicine, Thasso Post, Theragenomic Medicine No Comments ↓

August 28, 2019 – Immune checkpoint inhibitor (ICI) therapy is a form of cancer immunotherapy. The therapy targets immune checkpoints, key regulators of the immune system that when stimulated can dampen the immune response to an immunologic stimulus.

…

Read more ›

Tags: , , , , , , , , , , , , , , ,

Cancer therapies: Immune checkpoint inhibitors may kill you

Posted on by by Posted in Adverse Drug Reaction [ADR], New Research, New Safety Information, Thasso Post, Theragenomic Medicine No Comments ↓

…

Read more ›

Tags: , , , , , , , , , , , , , , , , , ,

Pembrolizumab (Keytruda): Clinical trials on hold

Posted on by by Posted in Adverse Drug Reaction [ADR], Regulatory Announcement, Thasso Post, Theragenomic Medicine No Comments ↓

September 2, 2017 – The American Food & Drug Administration (FDA) has announced that two clinical trials with Pembrolizumab (Keytruda) in patients with multiple myeloma have been put on hold. The FDA informs the public, health care professionals, and oncology clinical investigators about the risks associated with the use of Pembrolizumab (Keytruda) in combination with dexamethasone and an immunomodulatory agent (Lenalidomide (Revlimid) or Pomalidomide (Pomalyst)) for the treatment of patients with multiple myeloma.

…

Read more ›

Tags: , , , , , , , , , , ,

Biomarker-guided Larotrectinib for all cancer types?

Posted on by by Posted in Genetic Background, Genetic Predisposition, New Research, On The Horizon, Personalized Medicine, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

June 09, 2017 –  It’s only a couple of days that the American Food & Drug Administration (FDA) approved for the first time a cancer treatment for any solid tumor, irrespective of the tumor’s original location, as long as the targeted tumor is carrying a specific genetic feature (i.e.,

…

Read more ›

Tags: , , , , , , , , , ,

First cancer treatment for any solid tumor with MSI-H or dMMR approved

Posted on by by Posted in Genetic Background, New Indication Approval, Personalized Medicine, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓
May 24, 2917 – The American Food & Drug Administration (FDA) just approved a major extension of the clinical indications for Pembrolizumab (Keytruda). For the first time,  a cancer treatment has been approved for any solid tumor, irrespective of the tumor’s original location, as long as the targeted tumor is carrying a specific genetic feature (i.e.,

…

Read more ›

Tags: , , , , , , , , ,

Risk of severe if not fatal skin reactions with Pembrolizumab (Keytruda)

Posted on by by Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine No Comments ↓

March 21, 2017 – Health Canada just communicated this important safety information: Cases of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) under treatment of patients with Pembrolizumab (Keytruda) have been reported internationally in the clinical trials and post-marketing setting.

…

Read more ›

Tags: , , , , , ,

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Posted on by by Posted in Genetic Background, New Research, On The Horizon, Thasso Post, Theragenomic Medicine No Comments ↓

September 06, 2016 – Genetic mutations associated with acquired resistance to PD-1 blockade in melanoma have been suspected to be involved in the clinical observation that while approximately 75% of objective responses to anti–programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years,

…

Read more ›

Tags: , , , , , , , , , ,

Pembrolizumab [Keytruda] for advanced melanoma: First PD-1 blocking drug to receive approval

Posted on by by Posted in New Drug Approval, Thasso Post, Theragenomic Medicine No Comments ↓

September 11, 2014 – The U.S. Food and Drug Administration today granted accelerated approval to Pembrolizumab (Keytruda) for treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.

Melanoma, which accounts for approximately 5 percent of all new cancers in the United States,

…

Read more ›

Tags: , , , ,

thasso: donate

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

RSS random genetics

  • Researchers identify new gene mutation in familial thyroid cancers November 20, 2019
    Researchers from Penn State College of Medicine identified a new gene mutation that may cause a type of familial thyroid cancer. Dr. Darrin Bann, an otolaryngology resident at the College of Medicine and lead author of the study, said that this mutation is the first and only mutation associated with familial thyroid cancer to be […]
  • Researchers develop new database of druggable fusion targets November 20, 2019
    When sections from two separate genes merge due to various factors, such as translocation or splicing, the hybrid that is formed is called a gene fusion. In recent years, it has been discovered that these fusion events play a vital role in the development of cancers and other complex diseases. However, there are very few […]
  • Early results of CRISPR gene-editing treatment shows promise in first human trials November 20, 2019
    Officials from Vertex Pharmaceuticals and CRISPR Therapeutics have announced that preliminary results from testing CRISPR gene-editing treatment in human patients with blood disorders show promise thus far. The joint project between the two firms is taking place at one location in Europe and another in the United States. The results have been posted on the […]
  • Whole-genome sequencing analysis to find more exact biomarkers November 20, 2019
    A new study from Uppsala University shows that whole-genome sequencing increases the precision of genetic studies, which in turn can improve our understanding of how to use biomarkers to discover disease. The results are published in the scientific journal Scientific Reports.
  • Complex organ models grown in the lab November 19, 2019
    Scientists at the University of Würzburg have successfully produced human tissues from stem cells. They have a complexity similar to that of normal tissue and are far superior to previous structures.

RSS random science

  • New study confirms American children and teens are consuming significantly less sugary drinks November 21, 2019
    According to a new study in the American Journal of Preventive Medicine, published by Elsevier, the share of children and adolescents consuming sugar-sweetened beverages (SSBs) and the calories they consume from SSBs declined significantly between 2003 and 2014.
  • New Alzheimer risk gene discovered November 21, 2019
    A new paper in the Journal of Neuropathology & Experimental Neurology finds a gene that may help explain a large part of the genetic risk for developing Alzheimer disease.
  • New type of e-cigarette vaping injury described in CMAJ November 21, 2019
    A research case report describing lung injury related to e-cigarette use in a 17-year-old Canadian may be the first documented case of a new form of damage from vaping products. The article, published in CMAJ (Canadian Medical Association Journal) provides new evidence on forms of lung injury that can result from vaping.
  • CUHK Faculty of Engineering develops novel imaging approach November 21, 2019
    By combining a compressive sensing algorithm with a digital holographic microscope, Prof. Shih-Chi CHEN of the Department of Mechanical and Automation Engineering, Faculty of Engineering, The Chinese University of Hong Kong (CUHK) and his research team have developed a high-speed imaging method. The new approach is able to produce two-photon microscopy images of a 3D […]
  • Cybershoppers make better buying decisions on PCs than phones -- Ben-Gurion U. researchers November 21, 2019
    This is the first study that differentiates between screen size and information reduction, which are often mixed up. The findings will be presented next month at the International Conference on Information Systems, the top academic conference in the field.
Top